Publications by authors named "P Theroux"
Background: Ticagrelor reduces ischemic risk in patients with prior myocardial infarction (MI). It remains unclear whether ischemic risk and the benefits of prolonged P2Y inhibition in this population remain consistent over time.
Objectives: The study sought to investigate the pattern of ischemic risk over time and whether the efficacy and safety of ticagrelor were similar early and late after randomization.
Importance: In the PEGASUS-TIMI 54 trial, treatment with ticagrelor reduced the incidence of cardiovascular death, myocardial infarction, or stroke by 15% to 16% among stable patients compared with placebo. However, more patients prematurely discontinued treatment with ticagrelor than with placebo.
Objective: To investigate the reasons and timing of discontinuation of treatment with ticagrelor among stable patients prior myocardial infarction.
Coronary plaque rupture mediating acute ST segment elevation myocardial infarction (STEMI) is associated with a systemic inflammatory response. Whether early temporal changes in inflammatory biomarkers are associated with angiographic and electrocardiographic markers of reperfusion and subsequent clinical outcomes is unclear. In the APEX-AMI biomarker substudy, 376 patients with STEMI had inflammatory biomarkers measured at the time of hospital presentation and 24 h later.
View Article and Find Full Text PDFVorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial.
Eur Heart J Acute Cardiovasc Care
March 2017
Background: Vorapaxar is a first-in-class protease-activated receptor-1 antagonist indicated for the reduction of cardiovascular death, myocardial infarction, and stroke in stable patients with prior atherothrombosis, who have not had a prior stroke or transient ischemic attack. The aims of this study were to investigate: 1) the role of vorapaxar in patients with severe coronary artery disease treated previously with coronary artery bypass grafting (CABG); and 2) safety in patients undergoing CABG while receiving vorapaxar.
Methods: TRA 2°P-TIMI 50 was a randomized, double-blinded, placebo-controlled trial of vorapaxar in 26,449 stable patients with prior atherothrombosis followed for a median of 30 months.
Article Synopsis
- MAPK-stimulated inflammation plays a role in heart disease and could potentially be targeted with the p38 MAPK inhibitor losmapimod, which showed promise in early trials for improving outcomes in heart attack patients.
- The LATITUDE-TIMI 60 study assessed the safety and efficacy of losmapimod in over 3,500 patients who had suffered an acute myocardial infarction, comparing it to a placebo over a 12-week period.
- Results indicated that losmapimod did not significantly reduce the combined risk of cardiovascular death or further heart issues compared to placebo, with a hazard ratio of 1.16, suggesting it may not provide the expected benefits in this patient population.